Administered as a once-weekly subcutaneous injection, tirzepatide works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby improving glycaemic control
Phase 2 Obesity Trial New England Journal of Medicine (2023) The pivotal Phase 2 obesity trial of retatrutide, published in the New England Journal of Medicine, enrolled 338 adults with obesity (BMI 30) or overweight with weight-related comorbidities
Other online telehealth pharmacies are selling compounded versions of GLP-1 medications, which can be purchased without insurance and are not subject to FDA review and approval
There is no agreement on the test duration, hypoglycaemia cut-off points or interpretation in asymptomatic subjects
Marc Jean-Gilles, DO, FACOG, at Abundant Life Healthcare to determine if GLP-1 medications are right for you
If you are using retatrutide alongside diabetes medications, the dose schedule remains the same, but medication adjustments should be anticipated at each step, particularly at the 4mg and 8mg transitions where GLP-1 receptor activation produces the most significant glucose-lowering effects
